ENVERIC BIOSCIENCES, INC. Net Fee Amt
ENVERIC BIOSCIENCES, INC. (ENVB) had Net Fee Amt of $1.73 thousand as of 2026-04-23, per its S-3 filed 2026-04-23.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-04-23
- 2026-04-23: Net Fee Amt $1.73K.
| Period end | Net Fee Amt |
|---|---|
| 2026-04-23 | $1.73K S-3 · filed 2026-04-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |